Key result
A proposed algorithm for managing platelet refractory patients outlines a stepwise approach from providing ABO-compatible and fresh platelets to selecting compatible platelets for alloimmunized cases.
Presents a proposed algorithm for managing thrombocytopenic patients refractory to platelet transfusions, addressing both alloimmunized and nonimmunized recipients.
May guide stepwise management of platelet refractoriness; leaves open prospective validation before practice adoption.
Refractoriness to platelet transfusions continues to be a major problem for many thrombocytopenic patients. A proposed algorithm for managing these patients is presented which proceeds from easily instituted changes in platelet transfusion therapy such as provision of ABO-compatible and "fresh" platelet transfusions to the more difficult and costly process of selecting compatible platelets for patients who are documented to be alloimmunized. For nonimmunized platelet refractory recipients, multiple clinical and drug factors that may adversely effect transfusion responses have been identified. Identifying which of these factors are causally associated with poor platelet responses in any given patient remains a substantial challenge.
No takes yet. Share an insight, caveat, or question.
Sherrill J. Slichter (1997) conducted a review in Platelet refractoriness in thrombocytopenic patients. Proposed management algorithm was evaluated. A proposed algorithm for managing platelet refractory patients outlines a stepwise approach from providing ABO-compatible and fresh platelets to selecting compatible platelets for alloimmunized cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: